Lactulose Maintenance Regimen for Cirrhosis

Dosing Guidelines

The American College of Gastroenterology recommends an initial dosing of 30-45 mL (20-30 g) of lactulose 3-4 times daily, titrated to achieve 2-3 soft bowel movements per day, with a strength of evidence based on clinical guidelines 1
If excessive bowel movements occur (more than 2-3 per day), the dose should be reduced to prevent complications, as recommended by the American Association for the Study of Liver Diseases 2

Lactulose reduces intestinal pH through bacterial degradation to acetic and lactic acids, which helps to reduce ammonia production, as supported by evidence from the Clinical and Molecular Hepatology journal 1
It increases lactobacillus count, which do not produce ammonia, and converts ammonia to ammonium, making it less absorbable, with a moderate level of evidence from the Clinical and Molecular Hepatology journal 3
Lactulose produces an osmotic laxative effect that helps eliminate ammonia, with a high level of evidence from the Clinical and Molecular Hepatology journal 3

Overuse of lactulose can lead to complications including dehydration, hypernatremia, severe perianal skin irritation, and may paradoxically precipitate hepatic encephalopathy, as warned by the American College of Gastroenterology and the American Association for the Study of Liver Diseases 1, 2
Bloating and flatulence are common dose-dependent side effects that may limit use, with a low level of evidence from the American Association for the Study of Liver Diseases 2

Rifaximin (400 mg three times/day or 550 mg twice/day) can be considered as an alternative or adjunct to lactulose in patients who do not respond adequately, as recommended by the Clinical and Molecular Hepatology journal with a moderate level of evidence 4
Lactitol can be used as an alternative to lactulose at an equivalent daily dose of 67-100 g, with a low level of evidence from the Clinical and Molecular Hepatology journal 4
Branched-chain amino acids (0.25 g/kg/day) may be beneficial as an ancillary treatment option, with a moderate level of evidence from the Clinical and Molecular Hepatology journal 4